Depression is associated with reduced levels of the monoamines in the brain, such as serotonin (5-HT). The selective 5-HT re-uptake inhibitors (SSRIs) are thought to restore the levels of 5-HT in the synaptic cleft by binding at the 5-HT re-uptake transporter preventing the re-uptake and subsequent degradation of 5-HT. This re-uptake blockade leads to the accumulation of 5-HT in the synaptic cleft and the concentration of 5-HT returns to within the normal range. This action of SSRIs is thought to contribute to the alleviation of the symptoms of depression. In the presence of the SSRI, small amounts of 5-HT continue to be degraded in the synaptic cleft.
Permissions for creative use of the resources from Neurotorium
Permission is granted to download images, slides and videos and use them in your own presentations, provided that copyright notices and the Neurotorium logo are not hidden or removed. For use in publications and on websites, proper attribution must be provided together with a link to Neurotorium.org